Dabrafenib
别名: GSK2118436, GSK2118436A
中文名称:达拉菲尼,达拉非尼
目录号:S2807 Purity: 99.99%
Dabrafenib是一种突变型BRAFV600E特异性抑制剂,无细胞试验中IC50为0.7 nM,作用于B-Raf(wt)和c-Raf效果分别低7和9倍。
CAS: 1195765-45-7
客户使用Selleck的Dabrafenib发表文献295篇
- Nature, 2024 10.1038/s41586-024-08257-4
- Nature, 2024 629(8013):927-936
- Cancer Cell, 2024 S1535-6108(24)00119-3
- Nat Biotechnol, 2024 10.1038/s41587-024-02512-9
- Nat Genet, 2024 10.1038/s41588-024-01948-8
- Drug Resist Updat, 2023 71:100993
- Nat Cancer, 2023 4(2):240-256
- Nat Cancer, 2023 4(9):1292-1308
- Cancer Cell, 2022 S1535-6108(21)00662-0
- Nat Genet, 2022 54(7):976-984
- Nat Cell Biol, 2022 10.1038/s41556-022-00854-7
- Nat Biotechnol, 2021 10.1038/s41587-021-00837-3
- Mol Cancer, 2021 20(1):107
- Nat Genet, 2021 53(1):76-85
- Cell, 2020 182(3):685-712.e19
- Cancer Cell, 2020 37(3):387-402
- Nature, 2019 575(7781):203-209
- Nat Med, 2018 24(2):203-212
- Cell, 2018 173(6):1413-1425
- Cancer Discov, 2018 8(4):417-427
- Nat Biomed Eng, 2018 2(8):578-588
- Nat Biomed Eng, 2018 2(4):239-253
- Nature, 2017 550(7674):133-136
- Nature, 2017 551(7679):247-250
- Nat Med, 2016 22(9):1056-61
- Science, 2016 352(6282):189-96
- Cancer Cell, 2016 12;30(3):485-498
- Cell Res, 2015 10.1038/cr.2015.56
- Cancer Discov, 2015 5(4):358-67
- Cancer Discov, 2014 4(1):69-79
- Acta Neuropathol, 2024 147(1):44
- J Exp Clin Cancer Res, 2024 43(1):85
- EBioMedicine, 2024 107:105308
- MedComm (2020), 2024 5(8):e684
- Cell Mol Biol Lett, 2024 29(1):50
- Oncogene, 2024 43(3):155-170
- Oncogene, 2024 10.1038/s41388-024-03105-1
- Front Immunol, 2024 15:1334769
- Cancer Cell Int, 2024 24(1):8
- Cancers (Basel), 2024 16(5)1001
- Front Oncol, 2024 14:1191217
- Endocrine, 2024 10.1007/s12020-024-03887-0
- Cancer Biol Ther, 2024 25(1):2332000
- FEBS Lett, 2024 10.1002/1873-3468.14960
- bioRxiv, 2024 2024.01.09.574940
- Cell Rep Med, 2023 4(10):101200
- Mol Ther, 2023 10.1016/j.ymthe.2023.11.021
- EMBO Mol Med, 2023 15(3):e16629
- Cell Death Dis, 2023 14(7):441
- Br J Cancer, 2023 10.1038/s41416-023-02282-2
- Cell Rep, 2023 42(6):112570
- Oncogene, 2023 10.1038/s41388-023-02863-8
- Cells, 2023 13(1)73
- Cells, 2023 12(14)1855
- Commun Biol, 2023 6(1):1216
- Mol Cancer Ther, 2023 22(2):227-239
- Int J Mol Sci, 2023 24(6)5698
- Front Endocrinol (Lausanne), 2023 14:1247542
- Cancers (Basel), 2023 15(3)918
- Cancers (Basel), 2023 15(18)4477
- J Biol Chem, 2023 299(4):104595
- Heliyon, 2023 9(7):e17714
- Sci Adv, 2023 9(6):eade9238
- Sci Adv, 2023 9(35):eade7486
- bioRxiv, 2023 2023.01.24.525280
- Nat Commun, 2022 13(1):1100
- Nat Commun, 2022 13(1):7113
- Nat Commun, 2022 13(1):1381
- Cancer Commun (Lond), 2022 42(7):627-647
- Mol Cell, 2022 82(20):3919-3931.e7
- J Exp Clin Cancer Res, 2022 41(1):148
- Cancer Res, 2022 82(24):4555-4570
- EMBO Mol Med, 2022 14(12):e15677
- Cancer Lett, 2022 549:215921
- Cell Syst, 2022 13(10):830-843.e3
- Cell Death Dis, 2022 13(1):54
- Cell Rep, 2022 41(6):111601
- NPJ Precis Oncol, 2022 6(1):88
- EMBO Rep, 2022 23(11):e54746
- Mol Cancer Ther, 2022 21(6):1020-1029
- Front Pharmacol, 2022 13:1032975
- Pharmaceutics, 2022 14(2)310
- Pharmaceutics, 2022 14(3)590
- Cancers (Basel), 2022 14(21)5449
- Cancers (Basel), 2022 14(19)4930
- Cancers (Basel), 2022 14(2)357
- J Biol Chem, 2022 S0021-9258(22)00796-7
- Sci Rep, 2022 12(1):5573
- Life Sci Alliance, 2022 5(10)e202201445
- Life Sci Alliance, 2022 5(9)e202101235
- Endocr Relat Cancer, 2022 29(6):307-319
- Exp Dermatol, 2022 10.1111/exd.14677
- Drug Chem Toxicol, 2022 1-10
- Methods Enzymol, 2022 667:365-402
- Eur J Drug Metab Pharmacokinet, 2022 10.1007/s13318-021-00740-x
- Nat Commun, 2021 12(1):1747
- Nucleic Acids Res, 2021 49(8):4421-4440
- Cell Rep Med, 2021 2(7):100350
- Clin Cancer Res, 2021 10.1158/1078-0432.CCR-21-2660
- Cancer Res, 2021 81(20):5230-5241
- EBioMedicine, 2021 73:103646
- Cancer Immunol Res, 2021 10.1158/2326-6066.CIR-20-0905
- Cell Death Dis, 2021 12(7):699
- Cell Death Dis, 2021 12(1):85
- Cell Death Dis, 2021 12(9):816
- Oncogene, 2021 10.1038/s41388-020-01628-x
- Sci Signal, 2021 14(682)eabc1648
- Cell Death Discov, 2021 7(1):127
- Int J Mol Sci, 2021 22(11)5744
- Clin Sci (Lond), 2021 135(14):1631-1647
- J Clin Endocrinol Metab, 2021 dgab020
- Cancer Sci, 2021 112(9):3856-3870
- Int J Mol Sci, 2021 22(4)1801
- Biomolecules, 2021 11(2)153
- Cancers (Basel), 2021 13(19)4950
- Cancers (Basel), 2021 13(9)2175
- Cancers (Basel), 2021 13(14)3487
- Cancers (Basel), 2021 13(14)3635
- Eur J Pharmacol, 2021 906:174214
- Neoplasia, 2021 23(5):539-550
- Front Oncol, 2021 11:656453
- Gynecol Oncol, 2021 S0090-8258(21)00648-X
- Mol Carcinog, 2021 60(3):201-212
- Molecules, 2021 26(8)2141
- J Proteome Res, 2021 10.1021/acs.jproteome.1c00331
- Cell Cycle, 2021 1-11
- Pigment Cell Melanoma Res, 2021 10.1111/pcmr.13014
- Oncol Rep, 2021 45(4)14
- Transl Lung Cancer Res, 2021 10(9):3737-3744
- Endocr Relat Cancer, 2021 28(5):311-324
- J Physiol Biochem, 2021 10.1007/s13105-021-00789-x
- Mol Imaging Biol, 2021 10.1007/s11307-021-01615-y
- Oncol Lett, 2021 22(5):745
- Sci Adv, 2021 7(24)eabg0390
- Biomed Chromatogr, 2021 e5205
- Nat Commun, 2020 11(1):3946
- Proc Natl Acad Sci U S A, 2020 202004707
- Proc Natl Acad Sci U S A, 2020 117(49):31105-31113
- Cancer Lett, 2020 495:135-144
- Cell Death Dis, 2020 11(11):973
- Br J Cancer, 2020 122(6):789-800
- Eur J Cancer, 2020 144:17-30
- Cell Commun Signal, 2020 18(1):156
- Acta Pharmacol Sin, 2020 13
- Oncogene, 2020 39(20):4132-4154
- EMBO Rep, 2020 e50163
- ESMO Open, 2020 5(4):e000707
- Acta Neuropathol Commun, 2020 8(1):139
- PLoS Pathog, 2020 16;16(3):e1008341
- Int J Mol Sci, 2020 21(9)E3214
- Front Chem, 2020 23;8:184
- Oncotarget, 2020 11(44):3984-3997
- ACS Infect Dis, 2020 acsinfecdis.0c00486
- Cancers (Basel), 2020 12(11)E3205
- Cancers (Basel), 2020 22;12(2) pii: E512
- Cancers (Basel), 2020 12(10)E2981
- Neoplasia, 2020 22(9):376-389
- J Biol Chem, 2020 295(8):2407-2420
- Sci Rep, 2020 8;10(1):7826
- Sci Rep, 2020 27;10(1):5557
- Pigment Cell Melanoma Res, 2020 10.1111/pcmr.12932
- Biology (Basel), 2020 9(8):E218
- Pathol Oncol Res, 2020 10.1007/s12253-020-00834-y
- Vet Pathol, 2020 300985820967449
- Anticancer Res, 2020 40(4):1867-1874
- Sci Adv, 2020 22;6(21):eaaz8521
- Nat Commun, 2019 10(1):5143
- Nat Commun, 2019 10(1):2197
- Mol Cell, 2019 76(6):872-884
- Cell Death Differ, 2019 10.1038/s41418-019-0298-5
- Clin Cancer Res, 2019 25(21):6429-6442
- J Exp Clin Cancer Res, 2019 38(1):272
- J Exp Clin Cancer Res, 2019 38(1):56
- Cancer Res, 2019
- Cell Death Dis, 2019 10(4):281
- Mol Ther Nucleic Acids, 2019 14:287-300
- Cell Rep, 2019 26(1):65-78
- Cell Rep, 2019 29(3):573-588
- Eur J Cancer, 2019 109:137-153
- Acta Pharmacol Sin, 2019 40(2):268-278
- Acta Neuropathol Commun, 2019 7(1):128
- Acta Neuropathol Commun, 2019 7(1):119
- Biochem Pharmacol, 2019 169:113616
- Cancer Cell Int, 2019 19:223
- Int J Mol Sci, 2019 20(23)
- J Virol, 2019 10.1128/JVI.01791-19
- Target Oncol, 2019 14(5):619-626
- Cancers (Basel), 2019 11(9)
- Cancers (Basel), 2019 11(9)1381
- Transl Oncol, 2019 13(2):275-286
- Mol Pharm, 2019 16(9):3904-3915
- Sci Rep, 2019 9(1):10865
- Sci Rep, 2019 9(1):1225
- Pigment Cell Melanoma Res, 2019 10.1111/pcmr.12824
- Metabolites, 2019 9(11)
- ACS Chem Biol, 2019 10.1021/acschembio-00191
- Exp Gerontol, 2019 126:110691
- Surgery, 2019 10.1016/j.surg.2019.04.076
- Ann Biomed Eng, 2019 10.1007/s10439-019-02269-2
- PLoS One, 2019 14(6):e0217399
- Chembiochem, 2019 10.1002/cbic.201900266
- Photodermatol Photoimmunol Photomed, 2019 10.1111/phpp.12520
- Sci Adv, 2019 5(8):eaav8463
- Reprod Domest Anim, 2019 54(5):741-749
- Nat Commun, 2018 9(1):3440
- Nat Commun, 2018 9(1):2500
- Nat Commun, 2018 9(1):1466
- Mol Cell, 2018 69(6):923-937
- Mol Cell, 2018 70(5):920-935
- Nat Protoc, 2018 13(12):2827-2843
- Clin Cancer Res, 2018 24(23):6066-6077
- Clin Cancer Res, 2018 24(5):1090-1102
- Clin Cancer Res, 2018 24(14):3377-3385
- Cancer research, 2018 78(2):542-557
- Cell Syst, 2018 7(2):161-179
- Cell Death Dis, 2018 9(3):325
- Cell Chem Biol, 2018 25(2):175-184
- Breast Cancer Res, 2018 20(1):9
- Oncoimmunology, 2018 8(1):e1512456
- Mol Oncol, 2018 12(1):74-88
- Oncogenesis, 2018 7(9):67
- Neural Regen Res, 2018 13(2):252-256
- Mol Cancer Ther, 2018 17(4):806-813
- Mol Cancer Ther, 2018 17(1):84-95
- Front Pharmacol, 2018 9:856
- Oncotarget, 2018 9(92):36503-36514
- Oncotarget, 2018 9(17):13324-13336
- Oncotarget, 2018 9(51):29680-29697
- Oncotarget, 2018 9(47):28294-28308
- Neoplasia, 2018 20(5):467-477
- Sci Rep, 2018 8(1):10724
- Sci Rep, 2018 8(1):9991
- ACS Med Chem Lett, 2018 9(12):1199-1204
- NPJ Syst Biol Appl, 2018 4:39
- Acta Biochim Biophys Sin (Shanghai), 2018 50(4):355-361
- Hum Mol Genet, 2018 27(22):3974-3985
- Anticancer Res, 2018 38(11):6195-6200
- Small GTPases, 2018 10.1080/21541248.2018.1446697
- ProQuest, 2018
- Nat Commun, 2017 8:15623
- Nat Commun, 2017 8(1):823
- Cell Death Differ, 2017 24(1):83-97
- Clin Cancer Res, 2017 23(20):6203-6214
- Cancer Res, 2017 77(17):4684-4696
- Proc Natl Acad Sci U S A, 2017 114(29):E5930-E5939
- Oncogene, 2017 36(27):3842-3851
- Cell Mol Life Sci, 2017 74(19):3631-3645
- Elife, 2017 6
- Blood Adv, 2017 30;1(24):2147-2160
- J Med Chem, 2017 60(1):180-201
- Genome Res, 2017 27(4):613-625
- Arch Toxicol, 2017 91(8):2921-2938
- Int J Mol Sci, 2017 18(10)
- Oncotarget, 2017 8(40):68208-68220
- Oncotarget, 2017 8(64):107977-107990
- Oncotarget, 2017 8(52):90262-90277
- Oncotarget, 2017 9(9):8206-8222
- Sci Rep, 2017 7(1):15523
- Anal Bioanal Chem, 2017 409(15):3749-3756
- Oncol Rep, 2017 38(5):2741-2751
- Transl Lung Cancer Res, 2017 6(5):600-610
- Biochem Biophys Res Commun, 2017 489(1):14-20
- Biochim Biophys Acta Gen Subj, 2017 1861(11 Pt B):2980-2992
- Nat Commun, 2016 7:10274
- Autophagy, 2016 12(10):1776-1790
- Leukemia, 2016 30(4):937-46
- Elife, 2016 5
- Mol Cancer Ther, 2016 10.1158/1535-7163.MCT-15-0375
- Oncotarget, 2016 8(35):58021-58036
- Oncotarget, 2016 7(21):30453-60
- Oncotarget, 2016 7(46):75839-75853
- Oncotarget, 2016 7(12):15065-92
- J Biol Chem, 2016 291(34):17804-15
- Sci Rep, 2016 6:23713
- PLoS One, 2016 11(3):e0152104
- Cancer Biol Ther, 2016 17(7):778-84
- Mol Ther, 2015 23(5):931-942
- Cancer Res, 2015 75(1):216-29
- Cancer Immunol Res, 2015 3(6):602-9
- J Invest Dermatol, 2015 135(8):2021-2030
- Mol Cancer Ther, 2015 14(12):2700-11
- Oncotarget, 2015 6(38):40535-56
- Oncotarget, 2015 6(31):31792-804
- Eur J Pharmacol, 2015 762:283-92
- Antimicrob Agents Chemother, 2015 59(2):1088-99
- J Immunother, 2015 38(1):12-23
- Drug Metab Dispos, 2015 43(12):1934-7
- PLoS One, 2015 10(12):e0143847
- PLoS One, 2015 10(4):e0123410
- J Clin Invest, 2014 124(3):1406-17
- J Clin Invest, 2014 124(11):5074-84
- Cancer Res, 2014 10.1158/0008-5472.CAN-14-1392
- Cell Death Dis, 2014 5:e1278
- Transl Res, 2014 164(5):411-23
- The University of Texas, 2014 Lizee S
化学信息&溶解度
分子量 | 519.56 |
分子式 | C23H20F3N5O2S2 |
CAS号 | 1195765-45-7 |
Smiles | CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 192.47 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 192.47 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 91 mg/mL ( 175.14 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 4 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 192.47 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 192.47 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG 300
5%Tween80
50% ddH2O
浓度:5mg/ml
(9.62mM)
操作示例:以 1 mL 工作液为例,取 50 μL 100 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀使其澄清;向上述体系中加入50 μL Tween-80,混合均匀使其澄清;然后继续加入 500 μLddH2O定容至 1 mL。工作液请现配现用!
|
|
2%DMSO
Corn oil
浓度:3mg/ml
(5.77mM)
操作示例:以 1 mL 工作液为例,取20μL150mg/ml的澄清DMSO储备液加到980μL玉米油中,混合均匀。工作液请现配现用!
|
|
2% DMSO
45% PEG300
2%Tween80
50%ddH2O
浓度:3mg/ml
(5.77mM)
操作示例:以 1 mL 工作液为例,取20 μL 150 mg/ml的澄清DMSO储备液加到450 μL PEG300中,混合均匀使其澄清;向上述体系中加入20 μL Tween-80,混合均匀使其澄清;然后继续加入510 μL ddH2O定容至 1 mL。工作液请现配现用!
|
|
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:6mg/ml
(11.55mM)
操作示例:以 1 mL 工作液为例,取50μL120mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。